![Ilka Wicke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ilka Wicke
Private Equity Investor bij
Boehringer Ingelheim (Venture Capital)
Profiel
Ilka Wicke is an Investment Manager & Director at Boehringer Ingelheim (Venture Capital) since 2010.
She is also a Director at Pcovery ApS.
Previously, she worked as a Licensing Director at Boehringer Ingelheim GmbH, and as a Director at PROMETHERA Biosciences SA, Cardior Pharmaceuticals GmbH, and AgomAb Therapeutics NV.
Dr. Wicke holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Actieve functies van Ilka Wicke
| Bedrijven | Functie | Begin |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01-01-2010 |
Eerdere bekende functies van Ilka Wicke
| Bedrijven | Functie | Einde |
|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cell therapy products to treat liver diseases | Directeur/Bestuurslid | 06-04-2018 |
| AGOMAB THERAPEUTICS NV | Directeur/Bestuurslid | - |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Directeur/Bestuurslid | - |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | Corporate Officer/Principal | - |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of invasive fungal infections | Directeur/Bestuurslid | - |
Opleiding van Ilka Wicke
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
6
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | Health Technology |
Johann Wolfgang Goethe-Universität Frankfurt am Main
 Johann Wolfgang Goethe-Universität Frankfurt am Main Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cell therapy products to treat liver diseases | Health Technology |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of invasive fungal infections | Health Technology |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Health Technology |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
Kies MarketScreener 
